Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + losartan + chlorthalidone
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amlodipine + losartan + chlorthalidone is a fixed-dose combination (FDC) small molecule therapy developed by Hanmi Pharmaceutical for the treatment of hypertension. This triple-combination drug integrates three distinct antihypertensive mechanisms: amlodipine, a dihydropyridine calcium channel blocker that induces peripheral vasodilation; losartan, an angiotensin II receptor type 1 (AT1R) antagonist that inhibits the renin-angiotensin-aldosterone system; and chlorthalidone, a thiazide-like diuretic that promotes sodium and water excretion. By targeting multiple physiological pathways simultaneously, the combination is designed to provide superior blood pressure reduction and improved response rates compared to dual therapies or monotherapies. Hanmi also developed a low-dose variant (HCP1803, branded as Amoprel or Amosartan PLUS-L) intended for early-stage or first-line treatment of hypertension.
- Brand names
- Amosartan PLUSAmoprelAmosartan PLUS-L
- Other names
- amlodipine/losartan/chlorthalidoneamlodipine besylate/losartan potassium/chlorthalidone
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CA2 (Carbonic Anhydrase 2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)URAT1 (Uric Acid Transporter 1)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on amlodipine + losartan + chlorthalidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + losartan + chlorthalidone.